A phase 2 trial evaluating HLX22, in combination with trastuzumab and chemotherapy or combined with trastuzumab deruxtecan (T-DXd)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs HLX 22 (Primary) ; Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Antineoplastics
Indications Solid tumours
Focus Therapeutic Use

10 Dec 2024 New trial record
04 Dec 2024 According to Shanghai Henlius Biotech media release, company announced that the investigational new drug (IND) application for a phase 2 clinical trial of the company novel anti-HER2 monoclonal antibody (mAb), HLX22, in combination with trastuzumab and chemotherapy or combined with trastuzumab deruxtecan (T-DXd) has been approved by the China National Medical Products Administration (NMPA), for the treatment of HER2-expressing solid tumours.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com